EMD Millipore Launches PDReady™ Monoclonal Antibodies Kit for Accelerated Process Development
11 Dec 2012

EMD Millipore launched its PDReady™ Monoclonal Antibodies (MAbs) Kit for accelerating process development timelines. The kit is based on a robust process development template using state-of-the-art technologies for each purification operation. Every step within the template uses a technology already proven to successfully purify MAbs, allowing biopharmaceutical manufacturers to rapidly develop a reliable purification process that delivers high purity and yield.

The PDReady™ for MAbs Kit reduces the complexity of process development by providing a single integrated package including purification devices, precise protocols to guide process development, specific recommendations for required laboratory tools, support from EMD Millipore technical experts, and equipment such as the Cogent® Scale that is loaned to the customer. Each unit operation within the template is designed for convenient scaling from bench to clinic. By employing a proven template for MAb purification, the necessary experimentation for process development is drastically reduced, saving time, money and effort, while still developing a robust process.

"The PDReady™ for MAbs Kit leverages EMD Millipore's proven technologies to deliver a template for rapid and efficient downstream process development," said Vin Donovan, Vice President of Biopharm Process Solutions. "Our experience with these technologies in monoclonal antibody processes allows us to establish known process parameters, drastically reducing the experimentation required to achieve drug purity and yield targets. This speeds the time to clinic and ultimately commercial-scale production."

Request Info


Company website

EMD Millipore, a division of Merck KGaA, Darmstadt, Germany